NCT05815758View on ClinicalTrials.gov

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

PHASE3CompletedINTERVENTIONAL
Enrollment

512

Participants

Timeline

Start Date

April 20, 2023

Primary Completion Date

September 18, 2023

Study Completion Date

September 18, 2023

Conditions
Allergic Conjunctivitis
Interventions
DRUG

Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)

Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)

DRUG

Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution

Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution

Trial Locations (7)

21078

103- Seidenberg Protzko Eye Associates, Havre de Grace

22046

106- Emerson Research Institute, Inc., Falls Church

24502

102 - Piedement Eye Center, Lynchburg

27502

105- NC Eye Associates, Apex

38119

107 Total Eye Care, PA, Memphis

85225

104- Arizona Eye Center, Chandler

01810

101 - Andover Eye Associates, Andover

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY